MicroRNA-125b inhibits apoptosis and increases gemcitabine resistance by downregulating the expression of BAK1 in pancreatic ductal adenocarcinoma.

ABSTRACT:

Background

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies due to its aggressive progression and poor prognosis. Chemotherapy with gemcitabine is a standard treatment, yet the development of resistance severely limits gemcitabine effectiveness. Understanding the molecular mechanisms underlying this resistance is thus crucial for improving therapeutic outcomes. This study investigated the roles of microRNA-125b (miR-125b) in PDAC, focusing on its influence on cell proliferation and gemcitabine resistance.

Methods

We employed quantitative real-time polymerase chain reaction (qRT-PCR) to measure miR-125b levels in PDAC tissues and cell lines, and utilized cell proliferation assays, apoptosis assays, and luciferase reporter assays to elucidate

SUBMITTER: Sun J 

PROVIDER: S-EPMC12554503 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature